Evofosfamide, also formerly known as TH-302, is an investigational hypoxia-activated prodrug and is used to target cancerous cells under hypoxic conditions, which is a feature possessed by multiple solid tumors including glioblastoma and pancreatic cancer. Within regions of tumor hypoxia, evofosfamide releases bromo isophosphoramide mustard (Br-IPM), a potent DNA alkylating agent that kills tumor cells by forming DNA crosslinks. Once activated in hypoxic tissues, Br-IPM can also diffuse into surrounding oxygenated regions of the tumor and kill cells there via a “bystander effect”. Because of its preferential activation in the targeted hypoxic regions of solid tumors, evofosfamide may be less likely to produce broad systemic toxicity seen with untargeted cytotoxic chemotherapies.

Praziquantel, (-)- is oxopyrazinoisoquinoline derivative and a levorotated isomer of Praziquantel patented by Merck Patent G.m.b.H. as anthelmintics agent. In rabbits infested with S. japonicum, the therapeutic effect of Praziquantel, (-)-was greater than that of dl-praziquantel as rated by the number of the worms in tissues and by liver damage. Histopathological examination showed that liver egg granulomas in the levo-praziquantel group were fewer in no. and smaller in size and were predominantly composed of Pseudotubercles instead of eosinophilic abscesses. Levo-praziquantel is therapeutically superior to praziquantel, while dextro-praziquantel is almost ineffective.

Piprocurarium is a curarimimetic. It is antagonized by neostigmine. Piprocurarium is strongly vagolytic, producing tachicardia. Its duration of action is shorter than that of d-tubocurare and longer than that of succinylcholine. Piprocurarium is not hypotensive, is only slightly histaminogenic, is nonirritating to the veins, and can be mixed with all the anesthetic drugs. Piprocurarium has been offered for clinical trial as a brief-acting, nondepolarizing neuromuscular blocking drug. The drug appears to be anything but short acting. A persistent tachycardia and elevation in systolic and diastolic pressure invariably follows its intravenous injection. Alarming electrocardiographic changes occur, characterized by AV dissociation, depression of the ST segment, supraventricular tachycardia and, at times, inversion of the T waves. In view of these circulatory effects, it is doubtful that the drug will be useful clinically.

Solcitinib (also known as GSK2586184 or GLPG0778) is a selective Janus kinase 1 (JAK1) inhibitor, for the treatment of psoriasis, lupus, and ulcerative colitis. Galapagos NV's collaboration with GlaxoSmithKline has hit a roadblock. It was reported that its Big Pharma partner had hit the brakes on a Phase II study of GSK2586184 for lupus after a first look at the data failed to demonstrate a positive effect. And an exploratory Phase I/II of the same drug for ulcerative colitis was put on hold as investigators review the program.

Fevipiprant is a selective reversible antagonist of the prostaglandin D2 receptor (also known as CRTH2). It is currently in development for the treatment of allergic diseases.

Dapaconazole is an imidazolic compound developed by Biolab Sanus Farmaceutica for the treatment of fungal infections. Dapaconazole was investigated in several clinical trials. In patients with Pityriasis versicolor infections, dapaconazole demonstrated a good safety profile and was non-inferior to ketoconazole when topically applied as a 2% cream at a dose of 20 mg/day for 28 consecutive days. The drug is being investigated in phase 3 clinical trial for the treatment of Tinea Pedis.